Paloma Pharmaceuticals, Inc.
Records under this name other than patents Paloma Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Paloma Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE46,558 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis Formerly held Lapsed on the fee record Ended Jul 2, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 2, 2025 | USPTO record |
| US 9,381,187 | Radiation countermeasure agents Formerly held Lapsed on the fee record Ended Jul 5, 2024 · USPTO record | Lapsed on the fee record | Ended Jul 5, 2024 | USPTO record |
| US 6,599,921 | Non-steroidal estrogen receptor ligands Term ended Term ended Aug 21, 2021 · USPTO record | Term ended | Term ended Aug 21, 2021 | USPTO record |
| US 8,475,776 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis Formerly held Surrendered on reissue Surrendered on reissue Sep 26, 2017 · USPTO record | Surrendered on reissue | Surrendered on reissue Sep 26, 2017 | USPTO record |
| US 6,632,835 | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents Lapsed on the fee record Ended Oct 14, 2015 · USPTO record | Lapsed on the fee record | Ended Oct 14, 2015 | USPTO record |